All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Manipal Hospital Yeshwanthpur, the most common co-covered peer. We currently track 1 Biotech story that mention ABO-Incompatible Transplant, all published on March 21, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ABO-Incompatible Transplant
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Manipal Hospital Yeshwanthpur, the most common co-covered peer. We currently track 1 Biotech story that mention ABO-Incompatible Transplant, all published on March 21, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ABO-Incompatible Transplant. Shared-story counts are live from our verified record — not editorial picks.
Manipal Hospital Yeshwanthpur has achieved a major clinical milestone by completing over 500 kidney transplants, including 50 high-complexity ABO-incompatible procedures. This achievement, announced on World Kidney Day 2026, highlights the hospital's leadership in overcoming immunological barriers to organ donation.
ABO-Incompatible Transplant is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.